543 related articles for article (PubMed ID: 18155273)
1. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
2. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
3. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
[TBL] [Abstract][Full Text] [Related]
4. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
5. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
8. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
10. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
12. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
13. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
15. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
16. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
17. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
18. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
19. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Kennedy AW; Markman M; Webster KD; Kulp B; Peterson G; Rybicki LA; Belinson JL
Gynecol Oncol; 1998 Nov; 71(2):288-90. PubMed ID: 9826473
[TBL] [Abstract][Full Text] [Related]
20. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
